Abstract:BackgroundThe role of platelet–lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio (NLR) as independent prognostic markers in different tumors is well established. However, there is a limited review of the potential of NLR and PLR as predictors of treatment outcomes from immune checkpoint inhibitors (ICIs).ObjectiveTo establish a correlation between NLR and PLR and the potential of clinical benefit from ICIs.MethodsThe literature search was performed for studies that reported the association between NLR, PLR, and treatment outcomes among cancer patients treated with ICIs. The outcomes of interest were objective response rate (ORR), disease control rate (DCR), and progressive disease (PD). ORR was the summation of patients who achieved complete response and partial response. DCR included patients who achieved stable disease. PD was the proportion of patients who progressed, relapsed, or discontinued the treatment. Statistical analysis was performed using the STATA 12.0 package. Heterogeneity was determined by the I2 value. Quality assessment was performed using the Newcastle–Ottawa Scale. Egger’s test was used to establish publication bias and sensitivity analysis.ResultsA total of 40 papers that met the inclusion criteria were included in the systematic review. However, only 17 studies were used in the meta-analysis to determine the correlation between NLR, PLR, and treatment response. We found that treatment with ICIs and monitoring of outcomes and adverse events using PLR and NLR parameters have been studied in different tumors. Our analysis showed that low NLR correlated with higher ORR (OR = 0.62 (95% CI 0.47–0.81, p = 0.001) and higher DCR (OR = 0.23, 95% CI 0.14–0.36, p < 0.001). Higher NLR predicted a higher probability of PD (OR = 3.12, 95% CI 1.44, 6.77, p = 0.004). Similarly, low PLR correlated with higher ORR (OR = 0.69, 95% CI 0.5, 0.95, p = 0.025). Generally, patients with low NLR and PLR were more likely to achieve clinical benefit and better response (p-value < 0.001). Meanwhile, patients with high ratios were more likely to progress (p-value < 0.005), although there was significant heterogeneity among studies. There was no significant publication bias observed.ConclusionThe study showed that high NLR and PLR either at baseline or during treatment is associated with poorer treatment outcome. Therefore, these ratios can be utilized in clinical practice with other markers to determine treatment efficacy from immunotherapy.

Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with colorectal liver metastases: A systematic review

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Prognostic Significance Of Neutrophil-To-Lymphocyte Ratio In Colorectal Liver Metastasis: A Systematic Review And Meta-Analysis

The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: a systematic review and meta-analysis

Neutrophil to lymphocyte ratio predicts pattern of recurrence in patients undergoing liver resection for colorectal liver metastasis and thus the overall survival

Prognostic Value of Neutrophil-to-lymphocyte Ratio in Colorectal Cancer Liver Metastasis: A Meta-Analysis of Results from Multivariate Analysis

Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios Predict Chemotherapy Outcomes and Prognosis in Patients with Colorectal Cancer and Synchronous Liver Metastasis

The neutrophil-to-lymphocyte ratio and lactate dehydrogenase combined in predicting liver metastasis and prognosis of colorectal cancer

Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor

Neutrophil–lymphocyte Ratio and Platelet–lymphocyte Ratio As Potential Predictive Markers of Treatment Response in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

The Pretreatment Neutrophil‐lymphocyte Ratio May Predict Prognosis of Patients with Liver Cancer: A Systematic Review and Meta‐analysis

Prognostic Significance of the Neutrophil-to-lymphocyte Ratio in Primary Liver Cancer: a Meta-Analysis.

Prognostic Role of Neutrophil-to-lymphocyte Ratio in Colorectal Cancer: a Systematic Review and Meta-Analysis.

Elevated Neutrophil to Lymphocyte Ratio Might Predict Poor Prognosis for Colorectal Liver Metastasis after Percutaneous Radiofrequency Ablation

Lymph Node Ratio As a Valuable Prognostic Factor for Patients with Colorectal Liver-Only Metastasis Undergoing Curative Resection

Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis

High Neutrophil-To-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammation Index (SII) Are Markers of Longer Survival After Metastasectomy of Patients With Liver-Only Metastasis of Rectal Cancer

Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer

Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review

Neutrophil-to-lymphocyte Ratio for the Prognostic Assessment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies

Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival.